Work

Targeting tumor antigen Mesothelin by CAR-NK-92 cells as an effective therapy against ovarian cancer cells

Year: 2026
Type: article
Abstract: Background Ovarian cancer is typically diagnosed at an advanced stage with peritoneal metastases and remains associated with high relapse rates and limited therapeutic options. While chimeric antigen receptor (CAR)-based immunotherapies have demonstrated remarkable success in hematologic malignancies, their implementation against solid tumors remains challenging due to tumor heterogeneity and an immunosuppressive microenvironment. Mesothelin, a cell-surface glycoprotein overexpressed in ovarian cancer and largely absent in healthy tissues, represents a promising therapeutic target. Material and methods Third-generation anti-Mesothelin CAR constructs containing CD28, 4-1BB, and CD3ζ signaling domains were introduced into NK-92 cells using self-inactivating (SIN) alpharetroviral or lentiviral vectors. CAR expression, vector copy numbers, and cytotoxic activity were evaluated in 2D and 3D co-culture models employing ovarian cancer cell lines (OVCAR3, A2780) and primary patient-derived tumor cells. Cytotoxicity was assessed through live-cell imaging and flow cytometry. Results Mesothelin was highly expressed in ovarian cancer cell lines and patient tumor samples, but minimally detected in healthy ovarian tissues. Alpharetroviral anti-Mesothelin CAR-NK-92 cells exhibited potent, antigen-dependent cytotoxicity against Mesothelin-high OVCAR3 and primary ovarian cancer cells in 2D models and pronounced tumor reduction in 3D spheroid assays. Additionally, alpharetroviral CAR-NK-92 cells demonstrated greater cytotoxic activity compared to lentiviral counterparts. Conclusion Our findings demonstrate significant antitumor activity of alpharetroviral anti-Mesothelin CAR-NK-92 cells in vitro, underscoring Mesothelin as a promising therapeutic target in ovarian cancer. The favorable safety profile and high performance of alpharetroviral vectors support their further development as a platform for next-generation CAR-NK cell therapies against solid malignancies.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,290
OpenAlex ID: W7236839223
FWCI:
Cites: 41
Cited by:
Related to: 10